These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 9441713)

  • 21. Dose-response implications of the University of Alabama study of lymphohematopoietic cancer among workers exposed to 1,3-butadiene and styrene in the synthetic rubber industry.
    Sielken RL; Valdez-Flores C
    Chem Biol Interact; 2001 Jun; 135-136():637-51. PubMed ID: 11397418
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulatory developmental neurotoxicity and human risk assessment.
    Francis EZ
    Neurotoxicology; 1992; 13(1):77-84. PubMed ID: 1508435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of genetic toxicology data in U.S. EPA risk assessment: the mercury study report as an example.
    Schoeny R
    Environ Health Perspect; 1996 May; 104 Suppl 3(Suppl 3):663-73. PubMed ID: 8781402
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Implementing the National Academy's Vision and Strategy for Toxicity Testing: opportunities and challenges under the U.S. Toxic Substances Control Act.
    Locke PA; Bruce Myers D
    J Toxicol Environ Health B Crit Rev; 2010 Feb; 13(2-4):376-84. PubMed ID: 20574909
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Setting exposure standards: a decision process.
    Tilson HA; MacPhail RC; Crofton KM
    Environ Health Perspect; 1996 Apr; 104 Suppl 2(Suppl 2):401-5. PubMed ID: 9182048
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pesticide exposure and neurodevelopmental outcomes: review of the epidemiologic and animal studies.
    Burns CJ; McIntosh LJ; Mink PJ; Jurek AM; Li AA
    J Toxicol Environ Health B Crit Rev; 2013; 16(3-4):127-283. PubMed ID: 23777200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of reduced protocols for carcinogenicity testing of chemicals: report of a joint EPA/NIEHS workshop.
    Lai DY; Baetcke KP; Vu VT; Cotruvo JA; Eustis SL
    Regul Toxicol Pharmacol; 1994 Apr; 19(2):183-201. PubMed ID: 8041916
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Scientific and regulatory issues relevant to assessing risk for developmental neurotoxicity: an overview.
    Rees DC; Francis EZ; Kimmel CA
    Neurotoxicol Teratol; 1990; 12(3):175-81. PubMed ID: 2196418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. U.S. EPA's IRIS assessment of 2-butoxyethanol: the relationship of noncancer to cancer effects.
    Gift JS
    Toxicol Lett; 2005 Mar; 156(1):163-78. PubMed ID: 15705494
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A cancer risk assessment of di(2-ethylhexyl)phthalate: application of the new U.S. EPA Risk Assessment Guidelines.
    Doull J; Cattley R; Elcombe C; Lake BG; Swenberg J; Wilkinson C; Williams G; van Gemert M
    Regul Toxicol Pharmacol; 1999 Jun; 29(3):327-57. PubMed ID: 10388618
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Developmental neurotoxicity guideline study: issues with methodology, evaluation and regulation.
    Tsuji R; Crofton KM
    Congenit Anom (Kyoto); 2012 Sep; 52(3):122-8. PubMed ID: 22925212
    [TBL] [Abstract][Full Text] [Related]  

  • 32. What to do at low doses: a bounding approach for economic analysis.
    Griffiths CW; Dockins C; Owens N; Simon NB; Axelrad DA
    Risk Anal; 2002 Aug; 22(4):679-88. PubMed ID: 12224742
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Computational toxicology as implemented by the U.S. EPA: providing high throughput decision support tools for screening and assessing chemical exposure, hazard and risk.
    Kavlock R; Dix D
    J Toxicol Environ Health B Crit Rev; 2010 Feb; 13(2-4):197-217. PubMed ID: 20574897
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mode of action and the assessment of chemical hazards in the presence of limited data: use of structure-activity relationships (SAR) under TSCA, Section 5.
    Auer CM; Nabholz JV; Baetcke KP
    Environ Health Perspect; 1990 Jul; 87():183-97. PubMed ID: 2269224
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk assessment: the default conservatism controversy.
    Barnard RC
    Regul Toxicol Pharmacol; 1995 Jun; 21(3):431-8. PubMed ID: 7480897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improving cancer dose-response characterization by using physiologically based pharmacokinetic modeling: an analysis of pooled data for acrylonitrile-induced brain tumors to assess cancer potency in the rat.
    Kirman CR; Hays SM; Kedderis GL; Gargas ML; Strother DE
    Risk Anal; 2000 Feb; 20(1):135-51. PubMed ID: 10795346
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lessons learned in applying the U.S. EPA proposed cancer guidelines to specific compounds.
    Andersen ME; Meek ME; Boorman GA; Brusick DJ; Cohen SM; Dragan YP; Frederick CB; Goodman JI; Hard GC; O'Flaherty EJ; Robinson DE
    Toxicol Sci; 2000 Feb; 53(2):159-72. PubMed ID: 10696764
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mixture toxicity, cumulative risk, and environmental justice in United States federal policy, 1980-2016 : Why, with much known, was little done?
    Sprinkle RH; Payne-Sturges DC
    Environ Health; 2021 Sep; 20(1):104. PubMed ID: 34535123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Science and decisions: advancing risk assessment.
    Abt E; Rodricks JV; Levy JI; Zeise L; Burke TA
    Risk Anal; 2010 Jul; 30(7):1028-36. PubMed ID: 20497395
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Harmonization of cancer and noncancer risk assessment: proceedings of a consensus-building workshop.
    Bogdanffy MS; Daston G; Faustman EM; Kimmel CA; Kimmel GL; Seed J; Vu V
    Toxicol Sci; 2001 May; 61(1):18-31. PubMed ID: 11294970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.